Jing Ye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jing Ye has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Hui Liu
Second Affiliated Hospital, Anhui Medical University, Hefei, China
1 shared publicationLing Zheng
Second Affiliated Hospital, Anhui Medical University, Hefei, China
1 shared publication- Rongyu Liu
Department of Pulmonary, Anhui Geriatric Institute, The First Affiliated Hospital of Anhui Medical University, Jixi Road 218, Hefei, Anhui 230022, China
1 shared publication Zhi‐Li Xu
Second Affiliated Hospital, Anhui Medical University, Hefei, China
1 shared publication
Latest Publications
- Open Access
- 11 August 2019
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 33 (9) , e22990
Identification of a multidimensional transcriptome prognostic signature for lung adenocarcinoma
Background: Lung adenocarcinoma (LUAD) is one of the leading contributors to cancer‐related deaths worldwide. The objective of the current study is to identify a multidimensional transcriptome prognostic signature by combining protein‐coding gene (PCG) with long non‐coding RNA (lncRNA) for patients with LUAD.Methods: We obtained LUAD PCG and lncRNA expression profile data from three datasets in the Gene Expression Omnibus database and conducted survival analyzes for these individuals.Results: We established a predictive model comprising the three PCGs (NHLRC2, PLIN5, GNAI3), and one lncRNA (AC087521.1). This model segregated patients with LUAD into low‐ and high‐risk groups based on significant differences in survival in the training dataset (GSE31210, n = 226, log‐rank test P < .001). Risk stratification of the model was subsequently validated in other two test datasets (GSE37745, n = 106, log‐rank test P < .001; GSE30219, n = 85, log‐rank test P = .006). Time‐dependent receiver operating characteristic (timeROC) curve analysis demonstrated that the model correlated strongly with disease progression and outperformed pathological stage in terms of prognostic ability. Cox proportional hazards regression analysis revealed that the signature could serve as an independent predictor of clinical outcomes in patients with LUAD.Conclusions: We describe a novel multidimensional transcriptome signature that can predict survival probabilities in patients with LUAD.
- 11 August 2019
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 33 (9) , e22990
Open AccessIdentification of a multidimensional transcriptome prognostic signature for lung adenocarcinoma
Background: Lung adenocarcinoma (LUAD) is one of the leading contributors to cancer‐related deaths worldwide. The objective of the current study is to identify a multidimensional transcriptome prognostic signature by combining protein‐coding gene (PCG) with long non‐coding RNA (lncRNA) for patients with LUAD.Methods: We obtained LUAD PCG and lncRNA expression profile data from three datasets in the Gene Expression Omnibus database and conducted survival analyzes for these individuals.Results: We established a predictive model comprising the three PCGs (NHLRC2, PLIN5, GNAI3), and one lncRNA (AC087521.1). This model segregated patients with LUAD into low‐ and high‐risk groups based on significant differences in survival in the training dataset (GSE31210, n = 226, log‐rank test P < .001). Risk stratification of the model was subsequently validated in other two test datasets (GSE37745, n = 106, log‐rank test P < .001; GSE30219, n = 85, log‐rank test P = .006). Time‐dependent receiver operating characteristic (timeROC) curve analysis demonstrated that the model correlated strongly with disease progression and outperformed pathological stage in terms of prognostic ability. Cox proportional hazards regression analysis revealed that the signature could serve as an independent predictor of clinical outcomes in patients with LUAD.Conclusions: We describe a novel multidimensional transcriptome signature that can predict survival probabilities in patients with LUAD.